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668Background: Left ventricular assist devices are increasingly used to treat patients with advanced and otherwise
refractory heart failure as bridge to transplant or destination therapy. We evaluated a new miniaturized left ven-
tricular assist device that requires minimal surgery for implantation, potentially allowing implantation in earlier
stage heart failure.
Methods: HeartWare (Miami Lakes, Fla) developed transapical miniaturized ventricular assist device. Acute
(n ¼ 4), 1-week (n ¼ 2), and 30-day (n ¼ 4) bovine model experiments evaluated hemodynamic efficacy and
biocompatibility of the device, which was implanted through small left thoracotomy with single insertion at
apex of left ventricle without cardiopulmonary bypass. The device outflow cannula was positioned across the
aortic valve. The international normalized ratio was maintained between 2.0 and 2.5 with warfarin. Hemody-
namic, echocardiographic, fluoroscopic, hematologic, and blood chemistry measurements were evaluated.
Results: The device was successfully implanted through the left ventricular apex in all 10 animals. The device
was operated at 15,000 1000 rpm (power consumption, 3.5–6.0 W). The device maintained normal end-organ
perfusion with no significant hemolysis (0–30 mg/dL). There were no pump failures or device-related compli-
cations. At autopsy, no abnormalities were seen in endocardium, aortic valve leaflets, or aortic root. There was
no evidence of thromboembolism or abnormalities in any peripheral end organs.
Conclusions:We successfully demonstrated feasibility of a novel intraventricular assist device that can be com-
pletely implanted through left ventricular apex. This transapical surgical approach eliminates needs for sternot-
omy, device pocket, cardiopulmonary bypass, ventricular coring, and construction of an outflow graft
anastomosis. (J Thorac Cardiovasc Surg 2011;142:668-74)Mechanical circulatory support has emerged as an important
treatment option for patients with end-stage heart failure.
Several prospective clinical trials have demonstrated both
significant quality of life and survival benefits in patients re-
ceiving left ventricular assist devices (LVADs) relative to
those treated with optimal medical management alone.1-3
Significant clinical experience has now accumulated with
the use of the LVAD both as a bridge to transplant and as
permanent use or destination therapy.4
The incidence of serious adverse events, including infec-
tion, bleeding, thromboembolism, and right ventricular
dysfunction, associated with LVAD insertion has limited
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The Journal of Thoracic and Cardiovascular Surgfailure.1 First-generation pulsatile-flow LVADs have been
effective in providing mechanical unloading of the heart
and restoring normal hemodynamics and end-organ perfu-
sion but are larger, have limited durability because of several
moving and contacting parts, require valves to maintain uni-
directional flow, and require external venting through a large
percutaneous drive line. These limitations have led to the de-
velopment of smaller continuous-flow LVADs (axial and
centrifugal) with fewer moving parts, resulting in higher du-
rability. Further, inflow and outflow conduits do not require
valves to maintain antegrade flow. External venting is not
needed, allowing use of smaller caliber percutaneous leads.
Recent clinical data has demonstrated a favorable risk pro-
file for continuous-flow LVAD relative to first-generation
pulsatile designs.5-8 Newer generation designs use mag-
netic coupling and hydrodynamic bearings, allowing
a noncontact bearing design that further reduces sources
of friction and wear, with the potential to enhance durability
and decrease blood activation.8
Implantation of one of these continuous-flow devices still
requires a major open cardiac surgical procedure, typically
requiringmedian sternotomy, the creation of a preperitoneal
or intraperitoneal device pocket, and the use of cardiopul-
monary bypass. Long-term implantable LVADs tradition-
ally are placed with inflow to the device from the left
ventricular apex and outflow to the ascending aorta, withery c September 2011
Abbreviations and Acronyms
LVAD ¼ left ventricular assist device
MVAD ¼ miniature ventricular assist device
Slaughter et al Evolving Technology/Basic Scienceconstruction of an anastomosis between the aorta and out-
flow conduit. As a result, device therapy has traditionally
been offered only to patients in late stages of advanced heart
failure. More recently, these devices have been placed retro-
grade in an indwelling transaortic valve configuration.9-12
This newer design enables rapid percutaneous placement
without the need for a major surgical procedure. The
catheter-based LVADs have been shown to provide ade-
quate mechanical unloading of the ventricle and restore nor-
mal end-organ perfusion without damaging aortic valve
leaflets or aortic root structures. Current transvalvular de-
vices are designed for short-term support and placed
through the femoral vessels, however, rendering the patient
immobile and at risk for infection, without the possibility
for discharge and outpatient rehabilitation.
The miniature ventricular assist device (MVAD; Heart-
Ware Inc, Miami Lakes, Fla) is a continuous axial–flow
pump with a wide-bladed impeller and hydrodynamic fluid
bearings. The MVAD was developed from proprietary
HeartWare ventricular assist device technology (Heart-
Ware), which is currently in clinical trials.13 An intraven-
tricular configuration of the MVAD was developed to
allow transapical placement with an outflow cannula ad-
vanced antegrade across the aortic valve. This configura-
tion offers the advantages of transapical placement
without the use of cardiopulmonary bypass, ease of implan-
tation without the need for ventricular coring or construc-
tion of an outflow graft anastomosis, and placement with
less invasive surgical approaches (through a subcostal inci-
sion or a small thoracotomy). The design and feasibility
testing to evaluate hemodynamic efficacy and biocompati-
bility of the MVAD in acute and long-term large animal
models are presented.E
T
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SMATERIALS AND METHODS
Transapical MVAD
The MVAD is designed for intraventricular implantation with an out-
flow cannula that crosses the aortic valve. The device can be inserted either
through a subcostal incision or through a small left thoracotomy to access
the left ventricular apex. The MVAD consists of an anchor section that is
attached to the external surface of the myocardium near the apex, a stand-
pipe section that carries the drive cables external to the left ventricle and
holds the pump housing off of the internal myocardial surface, a pump
housing that contains the MVAD core assembly and a vane diffuser, and
an outflow cannula that crosses the aortic valve (Figure 1, top). The outflow
cannula tip uses a trilobar diffuser design to provide a radial force compo-
nent to the outflow, which minimizes the radial movement of the outflow
cannula within the aorta. The anchor includes a sewing ring and is designed
for fixation of the device and hemostasis. The tip of the trilobar outflowThe Journal of Thoracic and Cacannula is immediately distal to the aortic root and proximal to the innom-
inate artery (Figure 1, bottom). The MVAD length can be adjusted from
14.5 to 15.5 cm. Its (greatest diameter is 1.75 cm, and weighs 15 g. The
priming volume is 15 ml, and it is capable of generating flows ranging
from 1 to 5 L/min; however, sustained flow rates less than 2.5 L/min
may require additional monitoring of anticoagulation status. Operational
pump speed ranges between 12,000 and 20,000 rpm. The MVAD flow is
adjusted by varying the revolutions per minute set point on the controller
through the clinical monitor system, which is similar to the one used for
the HeartWare ventricular assist device.
An impeller with dual hydrodynamic bearings on each blade was
developed for the MVAD. The impeller is constructed from a single piece
of biocompatible, machinable, abrasion-resistant, and magnetizable
platinum-based alloy. The single-piece platinum alloy allows each of the
bladelike projections to be magnetized as a single, large magnetic pole,
which provides a strong electromagnetic coupling to a standard radial mo-
tor stator. Further, this strong coupling provides sufficient axial stiffness to
keep the impeller properly aligned within the device without the need for
mechanical support structures. The impeller radial suspension is accom-
plished through 2 hydrodynamic bearings, 1 in front and 1 behind the center
of mass for enhanced rotor dynamic stability. The simplicity of these im-
pellers built with the platinum alloy eliminates subassembly and the
need for abrasion-resistant coatings. The passive impeller suspension
system eliminates the requirement for upstream and downstream flow
structures.
TheMVAD core assembly consists of the impeller, a zirconium ceramic
tube to contain the impeller, and a conventional radial motor stator. Zirco-
nium ceramic was used because of its resistance to abrasion damage and
minimal eddy current losses. The motor stator is a conventional 12-V,
6-slotted design. Conventional radial motor stator design and weld rings
allows for simple, hermetic housings in a variety of configurations. The
exit cable is 4 mm in diameter and is covered with velour fabric.
Animal Model
The MVAD was tested in acute (n ¼ 4) and 1-week (n ¼ 2) and 30-day
(n ¼ 4) long-term experiments in a calf model (male Jersey calves 3–4
months old, 80–100 kg). The 80- to 100-kg calves were used to match
the ventricular apex to aortic valve lengths found in human beings. Animals
were allowed to acclimate for14 days before surgery. This study was con-
ducted in accordance with the Guide for the Care and Use of Laboratory
Animals’’ (National Institutes of Health publication 85-23, 1996, www.
nap.edu/catalog/5140.html), the Animal Welfare Act and Regulations,
and US Public Health Service Policy on the Humane Care and Use of
Laboratory Animals at the University of Louisville, an Association for
Assessment and Accreditation of Laboratory Animal Care–accredited
program. Use of the animals was approved by the institutional animal
care and use committee.
Surgical Technique
Each animal was anesthetized with 1% to 5% isoflurane and 100% ox-
ygen. An endotracheal tube was inserted to initiate mechanical ventilation.
A venous catheter was placed in the marginal ear vein before induction of
anesthesia. Tidal volume and respiratory rate were adjusted to maintain ar-
terial oxygen saturation at greater than 93%. Positive end-expiratory pres-
sure was maintained at 6 cm H2O. An orogastric tube was placed to
evacuate the rumen. The 1-week and 30-day animals received 2.2 mg/kg
flunixin meglumine intravenously and 0.01-mg/kg buprenorphine or
0.25- to 0.5-mg/kg butorphanol intravenously for analgesia, and 15- to
20-mg/kg cefazolin intravenously before surgery. The calf was placed on
the operating table in a right lateral recumbent position to facilitate a left
thoracotomy. The skin in the left neck and left thoracic areas was asepti-
cally prepared with chlorhexidine and sterile saline solution or alcohol
and sterilely draped. The left jugular furrow was dissected, isolating the
left jugular vein and carotid artery. A fluid-filled catheter was placed inrdiovascular Surgery c Volume 142, Number 3 669
FIGURE 1. Computer aided design model of miniaturized ventricular as-
sist device (MVAD, top). Primary components of this pump are anchor to
ventricular apex, standpipe to adjust position of pump inside ventricle
and across aortic valve, miniaturized ventricular assist device core assem-
bly, and outflow cannula.
Evolving Technology/Basic Science Slaughter et al
E
T
/B
Sthe jugular vein for drug infusion, blood sampling, and venous pressure
monitoring. A second fluid-filled catheter was placed into the carotid artery
for blood sampling (blood gas values) and arterial pressure monitoring.
Lactated Ringer solution was infused to maintain the central venous pres-
sure at 5 to 10 mm Hg. Fluid boluses of 0.9% sodium chloride solution
were also administered as needed to maintain pressure. Electrocardiogram,
arterial line pressure, central venous pressure, pulse oximetry, and body
temperature were monitored.
A lidocaine constant-rate infusion (100 mg/h) was initiated intrave-
nously and titrated for effect to prevent or control cardiac arrhythmias.
Boluses of 150 mg amiodarone were given intravenously as needed, also
to control cardiac arrhythmias. With the animal in a surgical plane of anes-
thesia (as determined by the loss of palpebral reflex, ventral pupil fixation,
and lack of response to painful stimuli), 0.1-mg/kg pancuronium bromide
or 30 mg succinylcholine (INN suxamethonium chloride) was adminis-
tered intravenously before initiation of left thoracotomy incision. Calves
were monitored continuously during anesthesia, and body temperature
was maintained with a warm water or air-circulating blanket. A left thora-
cotomy was performed at the 5th intercostal space to provide access and
exposure of the pulmonary artery, left ventricular apex, and descending
thoracic aorta.
The MVAD was filled with normal saline solution. Heparin (200–300
U/kg by intravenous central line) was administered. From 6 to 8 pledgeted
sutures were fixed to the left ventricular apex. After a small incision had
been made in the left ventricular apex, insertion and fixation of the
MVAD was completed without a need for bypass. Echocardiography and
fluoroscopy were performed on the calf to verify anatomic positioning of
the MVAD inside the aorta and to position the outflow cannula across
the aortic valve. If needed, the length of the standpipe was adjusted to en-
sure proper anatomic fit. The chronic animals were anticoagulated with
heparin for 72 hours after device implantation (activated coagulation
time target, 200–300 seconds) and then with warfarin to maintain an inter-
national normalized ratio of 2.0 to 3.0. Postoperatively, long-term animals
also received 15- to 20-mg/kg cefazolin twice daily intravenously for 7
days. Analgesia consisted of 1.1- to 2.2-mg/kg flunixin meglumine intrave-
nously 1 to 2 times daily for 3 days and 0.01-mg/kg buprenorphine twice
daily or 0.25- to 0.5-mg/kg butorphanol intravenously every 4 hours for 2
days.
Measurements and Analyses
In the acute calf experiments, a high-fidelity pressure catheter (Millar
Instruments, Houston, Tex) was used to measure left atrial pressure. A
high-fidelity dual pressure–volume conductance catheter (Millar Instru-
ments) was used for simultaneous measurement of left ventricular pres-
sure and volume and aortic pressure. Transit-time flow probes
(Transonics, Ithaca, NY) were used for measurement of aortic flow. All
transducers were precalibrated and postcalibrated against known stan-
dards to ensure measurement accuracy. Hemodynamic data were signal670 The Journal of Thoracic and Cardiovascular Surgconditioned and analog to digital converted at 400-Hz sampling rate for
digital analysis with a real-time good laboratory practice–compliant
data-acquisition system.14 Hemodynamic waveforms were recorded dur-
ing (1) baseline, (2) partial MVAD support, and (3) full MVAD support.
Baseline measurements were repeated between test conditions to ensure
that steady state baseline was maintained. Characterization of hemody-
namic parameter values was calculated with a Hemodynamic Evaluation
and Assessment Research Tool (HEART) program developed in Matlab
(MathWorks, Natick, Mass).15 Pressure, flow, and volume waveforms
were used to calculate landmark cardiovascular function parameters
(heart rate, stroke volume, cardiac output, and mean, systolic, and dia-
stolic pressures) on a beat-to-beat basis, with all beats in each data set av-
eraged to obtain a single representative mean value for each parameter.
Left ventricular pressure–volume loops were constructed by plotting ven-
tricular pressure against ventricular volume, with each loop representing 1
complete cardiac cycle (1 beat). Pressure–volume loops were used to cal-
culate external work (area inside pressure–volume loop) and to determine
ventricular filling and ejection pressures and changes in ventricular end-
diastolic, end-systolic, and stroke volumes. In the long-term animal ex-
periments, a flow probe was placed on the pulmonary artery (cardiac out-
put), and an arterial fluid-filled pressure line (mean arterial pressure) was
placed.
Echocardiography
Echocardiography was performed before, during, and after surgery to
assess cardiac function, blood flow, and device placement. A Philips
iE33 Echocardiography System with S8-3 transducer (Koninklijke Philips
Electronics NV, Amsterdam, The Netherlands) was used to obtain M-mode
and Doppler echocardiographic recordings. The transducer was covered by
a sterile latex sheath, with ultrasound gel inside the sheath to facilitate
acoustic transmission. Sterilized warm ultrasound gel was also placed on
the epicardium during imaging. Parasternal and apical views were used
to obtain images. Left ventricular end-diastolic and end-systolic volumes
and left ventricular ejection fraction (systolic function) were determined
from the apical 4-chamber view with the modified Simpson technique
(summation of discs). Left ventricular diastolic performance was assessed
by tissue Doppler imaging at the level of the mitral annulus. Right ventric-
ular size was indexed by the planimetered right ventricular end-diastolic
and end-systolic areas and right ventricular systolic function by the frac-
tional area change. The parasternal view was used to measure left ventric-
ular end-diastolic and end-systolic diameters and wall thicknesses
orthogonal to the long-axis of the left ventricle and to evaluate aortic valve
opening and MVAD placement. Regional wall thickening was assessed at
the anteroseptum and posterior wall. Color Doppler was used to detect and
quantify aortic regurgitation with the MVAD outflow cannula positioned
across the aortic valve (1–4þseverity scale).
Fluoroscopy
Fluoroscopy was performed to evaluate blood flow and anatomic posi-
tioning of the MVAD in cardiac catheterization laboratory (GE Innova
3100 All-Digital Cardiovascular Imaging System; GE Healthcare, a divi-
sion of General Electric Company, Chalfont St Giles, United Kingdom).
A cutdown to the right carotid artery was performed, and a vascular sheath
was placed in the carotid artery. An angiography catheter was placed in the
left ventricle for injection of radiopaque dye (50–100 mL, repeated 3–5
times) for flow visualization during fluoroscopy.
Hematology and Blood Chemistry
Venous blood samples (5 mL) were drawn to measure complete blood
cell count (Hemavet 950; CDC Technologies, Inc, Oxford, Conn), serum
chemistries (Jewish Hospital, Louisville, Ky) and plasma free hemoglobin
(HemoCue AB, €Angelholm, Sweden). During the acute animal experi-
ments, venous blood samples were withdrawn before MVAD implantation
(baseline), hourly during MVAD support, and after MVAD supportery c September 2011
FIGURE 2. Left ventricular (LV) pressure–volume loops demonstrating
effective mechanical unloading of ventricle with device support, as
evidenced by leftward shift of PV loop and reduced ventricular filling
and ejection pressures during miniaturized ventricular assist device
(VAD) support.
Slaughter et al Evolving Technology/Basic Science(baseline). During the long-term animal experiments, venous blood sam-
ples were collected before MVAD implantation (baseline) and after
MVAD implantation (every 12 hours for the first 2 days, daily from days
3–7, and weekly thereafter until the end of study) to analyze for temporal
changes in biochemical markers and quantify plasma free hemoglobin.
Histopathology
At the completion of the experiment, the MVAD was visually inspected
for evidence of clots, fractures, or other defects and photographed. End
organs were examined at necropsy for evidence of embolization and photo-
graphed. Histopathologic analyses were conducted on the aortic valve and
aortic root to ensure that the MVAD did not cause any injury to the aortic
valve or aorta. Aortic valve and vascular tissue blocks were sectioned at
5-mm thick and prepared for staining with hematoxylin and eosin for visu-
alization of histopathologic changes under light microscopy.RESULTS
Acute Large Animal Study
TheMVADwas successfully implanted through a limited
left thoracotomy, and the transapical placement of the
MVAD outflow cannula was confirmed by echocardiogra-
phy in all 4 acute animal experiments. There were noTABLE 1. Mean aortic flow, peak left ventricular pressure, left ventricul
negative rates of change in left ventricular pressure, mean aortic pres
baseline (no miniaturized ventricular assist device support), and with mini
Condition
AoFm
(L/min)
LVPsys
(mm Hg)
LVPed
(mm Hg)
LVEW
(mm Hg $ mL)
Baseline 5.7  1.5 91  6 12  0.4 6237  109
MVAD support 6.3  1.7 70  5 6  3.3 3299  1212
These data demonstrate unloading of native left ventricle and improvement in flow with m
(systolic) left ventricular pressure; LVPed, left ventricular end-diastolic pressure; LVEW, lef
dP/dt, negative rate of change in left ventricular pressure; AoPm, mean aortic pressure; Ao
ventricular assist device.
The Journal of Thoracic and Cacomplications related to device implantation or device per-
formance, and there was no apical bleeding. The MVAD re-
duced ventricular workload, as evidenced by lower systolic
and end-diastolic left ventricular pressures and smaller
ventricular volumes (Figure 2 and Table 1). Further,
MVAD support increased mean, systolic, and diastolic aor-
tic pressures and mean aortic flows (Table 1). Aortic pres-
sure pulsatility diminished with increasing MVAD support
(Figure 3). Collectively, these data demonstrated that the
MVAD effectively mechanically unloaded the native ventri-
cle. A careful necropsy of the calves demonstrated no
evidence of embolization in the brain, kidneys, spleen, or
heart; however, thrombus formation was observed at the
junction between the pump and the outflow cannula in 1
of the 4 experiments. A computational fluid dynamics study
conducted after the acute studies revealed an area of stasis at
the junction between the device and the outflow cannula.
The outflow cannula and cannula junction were redesigned
to eliminate this thrombus formation.Long-Term Large Animal Study
MVADs were successfully implanted in all 6 long-term
animals. Average speed (in rpm) and power consumption
(in watts) for the MVAD were within operational tolerances
throughout the duration of long-term support. There were
no device or controller system failures with the MVAD dur-
ing the study period. Therewere no apical bleeding issues in
any of the long-term animal experiments. The calves were
electively killed at 1 week (n ¼ 2) or 30 days (n ¼ 3) after
implant with 0.02-mg/kg xylazine intravenously followed
by 1 mL/10 lb body weight Beuthanasia-D Special (Inter-
vet/Schering-Plough Animal Health; Summit, NJ). One
30-day calf was electively killed at 14 days because of
pulmonary infection and ongoing respiratory distress not
related to MVAD support, as documented by necropsy.
Echocardiography and fluoroscopy demonstrated stable
device position of the MVAD within the ventricular cavity
(Figure 4). No aortic insufficiency was observed during
fluoroscopy or echocardiography. There were no changes
in hepatic function (alkaline phosphates, alanine amino-
transferase) or renal function (creatinine) from baseline,
suggesting that end-organ function was preserved. Plasmaar end diastolic pressure, left ventricular external work, positive and
sure, systolic aortic pressure, and diastolic aortic pressure during
aturized ventricular assist device support
þdP/dt
(mm Hg/s)
dP/dt
(mm Hg/s)
AoPm
(mm Hg)
AoPsys
(mm Hg)
AoPdia
(mm Hg)
791  40 1187  3 81  6 91  2 73  8
628  25 795  138 85  1 96  6 76  6
iniaturized ventricular assist device support. AoFm, Mean aortic flow; LVPsys, peak
t ventricular external work;þdP/dt, positive rate of change in left ventricular pressure;
Psys, systolic aortic pressure; AoPdia, diastolic aortic pressure;MVAD, miniaturized
rdiovascular Surgery c Volume 142, Number 3 671
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FIGURE 3. Aortic pressure (AoP), left ventricular pressure (LVP, dashed), and aortic flow (AoF) waveforms during baseline, partial miniaturized ventric-
ular assist device (MVAD) support, and full miniaturized ventricular assist device support. These data demonstrate that miniaturized ventricular assist device
unloads native ventricle similar to clinical ventricular assist devices.
FIGURE 4. Apex of left ventricle was accessed via thoracotomy.Miniaturized ventricular assist devicewas inserted through apex of left ventricle (top left).
Graphic illustration of implanted positioning of miniaturized ventricular assist device demonstrating transapical placement (top center). Fluoroscopy shows
good anatomic placement of miniaturized ventricular assist device in calf (top right). Echocardiographic color Doppler images demonstrate minimal aortic
regurgitation and adequate coaptation of aortic valve with transapical outflow cannula placement (bottom).
Evolving Technology/Basic Science Slaughter et al
672 The Journal of Thoracic and Cardiovascular Surgery c September 2011
E
T
/B
S
FIGURE 5. Average blood urea nitrogen (BUN), creatinine, plasma free
hemoglobin (pfHg), and international normalized ratio (INR) values for
all animals (n ¼ 4) were within clinically accepted thresholds throughout
30-day study period. These results demonstrate that miniaturized ventricu-
lar assist device carries minimal-device related hemolysis.
Slaughter et al Evolving Technology/Basic Sciencefree hemoglobin, blood urea nitrogen, creatinine, and inter-
national normalized ratio values were normal at all mea-
sured time points (Figure 5). At necropsy, all explanted
MVADs were free of thrombus formation. Histopathologic
examination demonstrated no abnormalities within the en-
docardium, mitral and aortic valve leaflets, or aortic root
(Figure 6). There was no evidence of thromboembolism
or abnormalities in any peripheral end-organ system.DISCUSSION
The transapical HeartWare MVAD has a number of po-
tential advantages relative to second-generation devices
currently in use today. The MVAD is significantly smaller
and requires a single insertion through the apex of the left
ventricle with the distal end of the device crossing the aortic
valve. Earlier generations of implantable LVADs have not
been specifically designed for myocardial recovery or
partial support but rather to serve as a therapeutic bridge
to heart transplant or as destination therapy.16 Patients in
New York Heart Association class III or early class IV heartFIGURE 6. Heart and aortic valve after animal was electively killed 30 days af
free of thrombi (left) in all long-term animals, and there was no damage to aort
with miniaturized ventricular assist device.
The Journal of Thoracic and Cafailure with preserved end-organ function may not require
complete mechanical cardiac replacement by LVAD and
may have a higher likelihood of recovery.17 Data from the
Interagency Registry for Mechanically Assisted Circulatory
Support demonstrate improved clinical outcomes when de-
vice therapy is implemented at earlier stages of heart fail-
ure.18,19 The unique wide-bladed design of this axial-flow
pump with incorporated hydrodynamic thrust bearings pro-
vides limited contact between the stator and the rotor. This
has the potential to limit the degradation of rotor compo-
nents and to minimize the potential for thrombosis. The ro-
tor design also incorporates a rigid magnetic coupling,
which may lead to reduced cellular trauma and heat gener-
ation, preventing activation of circulating blood elements
and minimizing hemolysis. Clinically, this may translate
into reductions in perioperative and postoperative bleeding
complications and the associated risks of transfusion.
The MVAD outflow cannula is positioned across the aor-
tic valve, and the device can be implanted off pump, without
a standard median sternotomy or ventricular coring, thus
using less invasive surgical techniques. The echocardio-
graphic and fluoroscopic data from 30-day implants indi-
cated that the aortic valve leaflets coapted around the
outflow cannula, and there were no significant retrograde
flows observed at the aortic valve. Further, no histopatho-
logic changes were identified in the aortic valve leaflets.
Longer-term implant (90 day) and recovery data need to
be completed for further investigation the potential effects
and clinical implications. In light of the current clinical
data suggesting that even mild aortic insufficiency at the
time of device implant potentially worsens during the sup-
port period in the continuous-flow pump population, further
evaluation is needed to determine whether aortic insuffi-
ciency would be a contraindication for this new pump.
The MVAD tested in the bovine model would be appropri-
ate for patients with a body surface area of 1.5 m2 or larger.
As a result of this feasibility study, variable-length cannulas
will be integrated into the MVAD design to accommodate
smaller, shorter intraventricular lengths. Further, the device
may be operated as either a partial support or a completeter miniaturized ventricular assist device implantation. Device was entirely
ic valve (right), demonstrating feasibility of long-term hemocompatibility
rdiovascular Surgery c Volume 142, Number 3 673
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myocardial condition of the patient. The transapical MVAD
implantation technique eliminates the need for a median
sternotomy, the creation of a device pocket, the use of car-
diopulmonary bypass, ventricular coring, and the construc-
tion of an outflow graft anastomosis. This could potentially
result in less surgical trauma, reduced operative time, and
reduced transfusion requirements, which could be another
incremental step forward to reduce adverse events associ-
ated with current continuous-flow LVAD support.CONCLUSIONS
The acute and long-term animal experiments clearly
demonstrate adequate anatomic fit, hemodynamic efficacy,
and potential long-term biocompatibility of the transapical
MVAD. Further studies will focus on the refinement of the
system controller, engineering of control strategies, and
longer-term 90-day studies.
We acknowledge and thank Cary Woolard, Mary Anne Hauck,
Laura and Karen Lott, and the University of Louisville Research
Resources Facilities veterinary staff for their assistance.References
1. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, DembitskyW,
et al. Long-termmechanical left ventricular assistance for end-stage heart failure.
N Engl J Med. 2001;345:1435-43.
2. Rogers JG, Butler J, Lansman SL, Gass A, Portner PM, Pasque MK, et al.
Chronic mechanical circulatory support for inotrope-dependent heart failure pa-
tients who are not transplant candidates: results of the INTrEPID Trial. J Am Coll
Cardiol. 2007;50:741-7.
3. Pae WE, Connell JM, Adelowo A, Boehmer JP, Korfer R, El-Banayosy A, et al.
Does total implantability reduce infection with the use of a left ventricular assist
device? The LionHeart experience in Europe. J Heart Lung Transplant. 2007;26:
219-29.
4. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B,
et al. Advanced heart failure treated with continuous-flow left ventricular assist
device. N Engl J Med. 2009;361:2282-5.674 The Journal of Thoracic and Cardiovascular Surg5. Miller LW, Pagani FD, Russell SD, John R, Boyle AJ, Aaronson KD, et al. Use of
a continuous-flow device in patients awaiting heart transplantation. N Engl
J Med. 2007;357:885-96.
6. John R, Kamdar F, Liao K, Colvin-Adams M, Boyle A, Joyce L. Improved sur-
vival and decreasing incidence of adverse events with the HeartMate II left ven-
tricular assist device as bridge-to-transplant therapy. Ann Thorac Surg. 2008;86:
1227-35.
7. Patel ND, Weiss ES, Schaffer J, Ullrich SL, Rivard DC, Shah AS, et al. Right
heart dysfunction after left ventricular assist device implantation: a comparison
of the pulsatile HeartMate I and axial-flow HeartMate II devices. Ann Thorac
Surg. 2008;86:832-40.
8. Pagani FD. Continuous-flow rotary left ventricular assist devices with ‘‘3rd gen-
eration’’ design. Semin Thorac Cardiovasc Surg. 2008;20:255-63.
9. Dixon S, Henriques JP, Mauri L, SjauwK, Civitello A, Kar B, et al. A prospective
feasibility trial investigating the use of the Impella 2.5 system in patients under-
going high-risk percutaneous coronary intervention (The PROTECT I Trial):
initial U.S. experience. JACC Cardiovasc Interv. 2009;2:91-6.
10. Meyns B, Dens J, Sergeant P, Herijgers P, Daenen W, Flameng W. Initial
experiences with the Impella device in patients with cardiogenic shock—Impella
support for cardiogenic shock. Thorac Cardiovasc Surg. 2003;51:312-7.
11. Vercaemst L, Vandezande E, Janssens P, Yvan T, Peter D, Meyns B. Impella:
a miniaturized cardiac support system in an era of minimal invasive cardiac
surgery. J Extra Corpor Technol. 2002;34:92-100.
12. Siess T, Nix C, Menzler F. From a lab type to a product: a retrospective view on
Impella’s assist technology. Artif Organs. 2001;25:414-21.
13. SlaughterMS, Sobieski MA 2nd, Tamez D, Horrell T, Graham J, Pappas PS, et al.
HeartWare miniature axial-flow ventricular assist device: design and initial fea-
sibility test. Tex Heart Inst J. 2009;36:12-6.
14. Koenig SC, Woolard C, Drew G, Unger L, Gillars K, Ewert D, et al. Integrated
data acquisition system for medical device testing and physiology research in
compliance with good laboratory practices. Biomed Instrum Technol. 2004;38:
229-40.
15. Schroeder MJ, Perrrault B, Ewert DL, Koenig SC. HEART: an automated beat-
to-beat cardiovascular analysis package using Matlab. Comput Biol Med. 2004;
34:371-88.
16. Holman WL, Bourge RC, Spruell RD, Murrah CP, McGiffin DC, Kirklin JK.
Ventricular assist devices as a bridge to cardiac transplantation. A prelude to
destination therapy. Ann Surgery. 1997;225:695-706.
17. Morley D, Litwak K, Ferber P, Spence P, Dowling R, Meyns B, et al. Hemody-
namic effects of partial ventricular support in chronic heart failure: results of
simulation validated with in vivo data. J Thorac Cardiovasc Surg. 2007;133:21-8.
18. Holman WL, Pae WE, Teutenberg JJ, Acker MA, Naftel DC, Sun BC, et al.
INTERMACS: interval analysis of registry data. J Am Coll Surg. 2009;208:
755-62.
19. Kirklin JK, Naftel DC, Stevenson LW, Kormos RL, Pagani FD, Miller MA, et al.
INTERMACS database for durable devices for circulatory support: first annual
report. J Heart Lung Transplant. 2008;27:1065-72.ery c September 2011
